Targeting Nociceptors in Hidradenitis Suppurativa
University of Massachusetts, Worcester
Summary
This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease Hidradenitis Suppurativa (HS). In this study, the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin reduces pathogenic inflammation.
Description
Botulinum toxin prevents vesicle fusion at nerve terminals thereby inhibiting neuropeptide release. The investigators will collect punch biopsies of lesional skin from HS patients before, and 1-2 months after botulinum toxin treatment (50U per axilla in 10 injections of 0.1mL) then perform flow cytometric, transcriptomic, and microscopic analysis of skin to determine if nonselective inhibition of neuropeptide release diminishes IL-17 driven skin inflammation.
Eligibility
- Age range
- 18–75 years
- Sex
- All
- Healthy volunteers
- No
Inclusion: * Adults between ages 18 and 75 years with established diagnosis of hidradenitis suppurativa (HS) * HS skin lesions of duration at least 1 year, HS skin lesions in at least two different body areas Exclusion: * Age \< 18 years or \> 75 years * pregnant or breastfeeding * neuromuscular disorder (ex. ALS, myasthenia gravis, Lambert-Eaton syndrome, myopathy) * medical co-morbidity that is a relative contraindication to skin biopsy procedure (ex. end stage congestive heart failure or coagulopathy) * active bacterial, fungal, or viral infection in the treatment area * known hypersensi…
Interventions
- DrugBotulinum toxin
Administration of botulinum toxin (50 units/100cm2 injected intradermally) into lesional skin
Location
- University of Massachusetts Chan Medical SchoolWorcester, Massachusetts